Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969788 | 0.87 | KEAP1 (0.35) | KEAP1DYRK1ANAMPTMEN1CYP1A2 | |
| SCHEMBL10183355 | 0.82 | DYRK1A (0.37) | KEAP1DYRK1ANAMPTTGFBR1MEN1 | |
| SCHEMBL24574151 | 0.79 | DYRK1A (0.35) | KEAP1DYRK1ANAMPTTGFBR1MEN1 | |
| SCHEMBL29837274 | 0.75 | NAMPT (0.40) | KEAP1DYRK1ANAMPTTGFBR1MEN1 | |
| SCHEMBL24574341 | 0.74 | NAMPT (0.34) | KEAP1DYRK1ANAMPTTGFBR1MEN1 | |
| SCHEMBL22109454 | 0.73 | KEAP1 (0.30) | KEAP1 | |
| SCHEMBL20132528 | 0.73 | KEAP1 (0.47) | KEAP1DYRK1ATGFBR1MEN1CYP1A2 | |
| SCHEMBL24978834 | 0.72 | KEAP1 (0.36) | KEAP1DYRK1ATGFBR1MEN1CYP1A2 | |
| SCHEMBL12489380 | 0.72 | MET (0.41) | KEAP1DYRK1ANAMPTTGFBR1MEN1 | |
| SCHEMBL22077198 | 0.72 | MET (0.31) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | KEAP1 1720/4885DYRK1A 1149/4885NAMPT 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.